Boston Scientific Corporation has closed the agreement with Endo International to purchase American Medical Systems' (AMS) Men's Health and Prostate Health businesses, for $1.6 billion in up-front cash and a potential additional $50 million milestone based on 2016 sales.
Article continues below
The acquisition positions Boston Scientific as a leader in urology, providing physicians and healthcare systems a comprehensive portfolio of proven technologies.
The transaction includes AMS' products for treating urologic conditions, including the minimally invasive GreenLight XPS and HPS Laser Therapy Systems for treating benign prostatic hyperplasia, the AMS 800 Urinary Control System for treating male incontinence and the AMS 700 Inflatable Penile Prosthesis for treating erectile dysfunction.
These technologies complement the Boston Scientific leading urology portfolio for the treatment of kidney stones and pelvic floor disorders, enabling further innovation for the company across five common urologic diseases that account for 50 percent of all urologic surgical procedures. The AMS women's health business is not part of the transaction.
The AMS Men's Health and Prostate Health businesses will be combined with the Boston Scientific Urology and Women's Health businesses. The joint businesses will become the Boston Scientific Urology and Pelvic Health business.
The business unit will also continue to invest in gynecologic surgical solutions for the treatment of abnormal uterine bleeding and uterine fibroids.
The acquisition is expected to result in annual pre-tax synergies in excess of $50 million by the end of 2018. On an adjusted basis, the transaction is expected to be breakeven to adjusted earnings per share in 2015, accretive by at least 3 cents in 2016, approximately 7 cents in 2017 and increasingly accretive thereafter.
The transaction is expected to be less accretive (or dilutive, as the case may be) on a GAAP basis 2015 through 2017, due to amortization expense and transaction and integration costs. ■